isoxazoles has been researched along with Non-alcoholic Fatty Liver Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd El-Aty, AM; Cho, W; Hacimuftuoglu, A; Jeong, JH; Jung, TW; Park, SY | 1 |
| Anstee, QM; Charlton, M; Fischer, L; Francque, S; Kochuparampil, J; Loomba, R; Pedrosa, M; Ratziu, V; Rinella, M; Sanyal, A; Seyedkazemi, S; Vaidyanathan, S | 1 |
| Badman, MK; Bao, D; Bursulaya, B; Chianelli, D; Chu, A; Groessl, T; Hernandez, ED; Hill, R; Huang, DJ; Joseph, SB; Kim, Y; Laffitte, B; Liu, B; Liu, X; Liu, Y; McNamara, P; Molteni, V; Nelson, J; Phimister, A; Prashad, M; Richmond, W; Roland, J; Rucker, PV; Sancho-Martinez, I; Schlama, T; Schmeits, J; Seidel, HM; Tully, DC; Wu, J; Zoll, J | 1 |
| Adorini, L; Anfuso, B; Rosso, N; Tiribelli, C | 1 |
| Cai, W; Chen, S; Du, J; Liu, Y; Lu, Y; Tian, X; Wang, W; Wang, Y; Xiao, Y | 1 |
| Chow, MD; Guo, GL; Lee, YH | 1 |
| Alper, PB; Bao, D; Bursulaya, B; Chianelli, D; Groessl, T; Joseph, SB; Kim, Y; Laffitte, B; Liu, B; McNamara, P; Molteni, V; Mutnick, D; Phimister, A; Rucker, PV; Schmeits, J; Seidel, HM; Tully, DC; Vidal, A; Williams, J; Wu, X; Zoll, J | 1 |
| Deng, Y; Huang, J; Liu, S; Lu, Y; Ning, G; Shen, W; Wang, H; Yang, J; Yang, Y; Zhang, D; Zhang, Q; Zhang, R; Zhu, R | 1 |
| Chen, M; Fu, BQ; Ma, X; Tao, LS; Xu, YP; Yao, J; Zhou, CS | 1 |
| Alawad, AS; Levy, C | 1 |
2 review(s) available for isoxazoles and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Topics: Azepines; Bile Acids and Salts; Carcinoma, Hepatocellular; Disease Progression; Energy Metabolism; Gene Expression Regulation; Glucose; Humans; Indoles; Isoxazoles; Liver; Liver Cirrhosis; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Receptors, Steroid | 2017 |
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
1 trial(s) available for isoxazoles and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Topics: Benzothiazoles; CCR5 Receptor Antagonists; Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Imidazoles; Isoxazoles; Liver Cirrhosis; Multicenter Studies as Topic; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Receptors, CCR2; Receptors, Cytoplasmic and Nuclear; Sulfoxides; Treatment Outcome | 2020 |
7 other study(ies) available for isoxazoles and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Valdecoxib attenuates lipid-induced hepatic steatosis through autophagy-mediated suppression of endoplasmic reticulum stress.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Endoplasmic Reticulum Stress; Hepatocytes; Isoxazoles; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Palmitates; RNA, Small Interfering; Sirtuins; Sulfonamides | 2022 |
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Topics: Animals; Benzothiazoles; Chenodeoxycholic Acid; Diet, High-Fat; Dogs; Humans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protein Structure, Tertiary; Rats; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2020 |
Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model.
Topics: Benzamides; Benzothiazoles; Bile Acids and Salts; Cell Line; Chenodeoxycholic Acid; Coculture Techniques; Collagen; Fatty Acids, Nonesterified; Hepatic Stellate Cells; Hepatocytes; Humans; Imidazoles; Isoxazoles; Liver; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Non-alcoholic Fatty Liver Disease; Protein Kinase Inhibitors; Pyridines; Receptors, Cytoplasmic and Nuclear; RNA-Binding Proteins | 2020 |
A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis.
Topics: Animals; Benzothiazoles; Bile Acids and Salts; Fibrosis; Humans; Isoxazoles; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Swine | 2021 |
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
Topics: Administration, Oral; Animals; Benzothiazoles; Biological Availability; Cholestasis; Dogs; Drug Evaluation, Preclinical; Fibroblast Growth Factors; Gene Expression Regulation; Humans; Isoxazoles; Male; Microsomes, Liver; Non-alcoholic Fatty Liver Disease; Piperidines; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Triglycerides | 2017 |
Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis.
Topics: Animals; Cells, Cultured; Chemokines; Disease Progression; Down-Regulation; Fatty Liver; Gene Expression Regulation; HEK293 Cells; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear | 2013 |
FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
Topics: Adult; Animals; Anti-Inflammatory Agents; Antigens, Differentiation; Apoptosis; Cell Line; Disease Models, Animal; Down-Regulation; Female; Humans; Inflammation Mediators; Isoxazoles; Lipopolysaccharides; Liver; Macrophage Activation; Macrophages; Male; Mice, Inbred C57BL; Middle Aged; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2014 |